Halozyme Therapeutics, Inc. (HALO) — Financial statements
Income statement, balance sheet, and cash flow for Halozyme Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,397↑37.6% | 1,015↑22.4% | 829↑25.6% | 660↑48.9% | 443 | |
| Cost of Revenue | 305↑91.6% | 159↓17.1% | 192↑38.1% | 139↑71.1% | 81 | |
| Gross Profit | 1,091↑27.5% | 856↑34.4% | 637↑22.3% | 521↑43.9% | 362 | |
| Operating Expenses | ||||||
| R&D Expenses | 81↑3.1% | 79↑3.5% | 76↑14.6% | 67↑86.7% | 36 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 193↑25.3% | 154↑3.5% | 149↑3.9% | 144↑185.2% | 50 | |
| Other Expenses | 0.00↓100.0% | 71↓3.7% | 74↑71.0% | 43 | 0.00 | |
| Operating Expenses | 275↓9.7% | 304↑1.7% | 299↑18.2% | 253↑194.5% | 86 | |
| Total Costs & Expenses | 580↑25.1% | 464↓5.7% | 492↑25.2% | 393↑134.5% | 167 | |
| Operating Results | ||||||
| Operating Income | 816↑48.0% | 551↑63.4% | 338↑26.2% | 268↓3.0% | 276 | |
| Depreciation & Amortization | 88↑8.3% | 81↓4.2% | 85↑70.9% | 50↑1556.4% | 3 | |
| EBITDA | 904↑37.7% | 657↑45.3% | 452↑43.2% | 316↑21.8% | 259 | |
| EBIT | 816↑41.9% | 575↑56.7% | 367↑38.1% | 266↑3.8% | 256 | |
| Interest & Other Income | ||||||
| Net Interest Income | -18↓0.2% | -18↑3.6% | -19↓10.7% | -17↓125.2% | -8 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 18↑0.2% | 18↓3.6% | 19↑10.7% | 17↑125.2% | 8 | |
| Non-Operating Income | 0.00↑100.0% | -24↑19.5% | -30↓1871.7% | 2↓91.6% | 20 | |
| Other Income / Expenses | -349↓6276.7% | 6↓47.4% | 11↑157.8% | -19↑32.0% | -27 | |
| Income Before Tax | 467↓16.2% | 557↑59.9% | 348↑39.9% | 249↑0.2% | 249 | |
| Income Tax Expense | 150↑32.7% | 113↑69.4% | 67↑42.6% | 47↑130.3% | -154 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 317↓28.6% | 444↑57.7% | 282↑39.3% | 202↓49.8% | 403 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 317↓28.6% | 444↑57.7% | 282↑39.3% | 202↓49.8% | 403 | |
| Bottom-Line Net Income | 317↓28.6% | 444↑57.7% | 282↑39.3% | 202↓49.8% | 403 | |
| EPS (Basic) | 2.64↓24.6% | 3.50↑64.3% | 2.13↑43.9% | 1.48↓48.3% | 2.86 | |
| EPS (Diluted) | 2.56↓25.4% | 3.43↑63.3% | 2.10↑45.8% | 1.44↓47.4% | 2.74 | |
| Weighted Average Shares | 120↓5.5% | 127↓3.9% | 132↓3.6% | 137↓2.7% | 141 | |
| Weighted Average Diluted Shares | 124↓4.3% | 129↓3.6% | 134↓4.6% | 141↓4.2% | 147 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.